Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning

Cardiovascular Research

Volumn 112, Issue 3, 2016, Pages 669-676

  Basalay, Marina V ^a,b   Mastitskaya, Svetlana ^a   Mrochek, Aleksander ^b   Ackland, Gareth L ^a,c   Del Arroyo, Ana Gutierrez ^c   Sanchez, Jenifer ^c   Sjoquist, Per Ove ^d   Pernow, John ^d   Gourine, Alexander V ^a   Gourine, Andrey ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b REPUBLICAN SCIENTIFIC AND PRACTICAL CENTRE CARDIOLOGY   (Belarus)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardioprotection; Glucagon like peptide 1; Myocardial infarction; Myocardial ischaemia; Parasympathetic; Remote ischaemic conditioning; Reperfusion; Vagus nerve

Indexed keywords

EXENDIN 4; EXENDIN 9; GLP1R PROTEIN, RAT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HORMONE ANTAGONIST; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PEPTIDE; PEPTIDE FRAGMENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN; STAT3 PROTEIN, RAT; VENOM;

ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE; DISEASE MODEL; DRUG EFFECTS; FEMORAL ARTERY; ISCHEMIC PRECONDITIONING; LIGATION; MALE; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PROCEDURES; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; SURGERY; VAGOTOMY; VAGUS NERVE;

ANIMALS; DISEASE MODELS, ANIMAL; FEMORAL ARTERY; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HORMONE ANTAGONISTS; ISCHEMIC PRECONDITIONING; LIGATION; MALE; MUSCARINIC ANTAGONISTS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PEPTIDE FRAGMENTS; PEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M3; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; VAGOTOMY; VAGUS NERVE; VENOMS;

EID: 85030991298     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw216     Document Type: Article

References (61)

1. Heusch G. Molecular basis of cardioprotection: Signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res 2015;116:674-699.
2. Heusch G, Bøtker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. J Am Coll Cardiol 2015;65:177-195.
3. Basalay M, Barsukevich V, Mastitskaya S, Mrochek A, Pernow J, Sjöquist PO, Ackland GL, Gourine AV, Gourine A. Remote ischaemic pre- A nd delayed postconditioning-similar degree of cardioprotection but distinct mechanisms. Exp Physiol 2012;97:908-917.
4. Bøtker HE, Kharbanda R, Schmidt MR, Bøttcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sørensen HT, Redington AN, Nielsen TT. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: A randomised trial. Lancet 2010;375:727-734.
5. White SK, Frohlich GM, Sado DM, Maestrini V, Fontana M, Treibel TA, Tehrani S, Flett AS, Meier P, Ariti C, Davies JR, Moon JC, Yellon DM, Hausenloy DJ. Remote ischemic conditioning reduces myocardial infarct size and edema in patients with STsegment elevation myocardial infarction. JACC Cardiovasc Interv 2015;8:178-188.
6. Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhauser M, Peters J, Jakob H, Heusch G. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: A single-centre randomised, double-blind, controlled trial. Lancet 2013;382:597-604.
7. Sloth AD, Schmidt MR, Munk K, Kharbanda RK, Redington AN, Schmidt M, Pedersen L, Sørensen HT, Bøtker HE; CONDI Investigators. Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur Heart J 2014;35:168-175.
8. Dickson EW, Reinhardt CP, Renzi FP, Becker RC, Porcaro WA, Heard SO. Ischemic preconditioning may be transferable via whole blood transfusion: Preliminary evidence. J Thromb Thrombolysis 1999;8:123-129.
9. Konstantinov IE, Li J, Cheung MM, Shimizu M, Stokoe J, Kharbanda RK, Redington AN. Remote ischemic preconditioning of the recipient reduces myocardial ischemiareperfusion injury of the denervated donor heart via a Katp channel-dependent mechanism. Transplantation 2005;79:1691-1695.
10. Shimizu M, Tropak M, Diaz RJ, Suto F, Surendra H, Kuzmin E, Li J, Gross G, Wilson GJ, Callahan J, Redington AN. Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: Evidence suggesting cross-species protection. Clin Sci (Lond) 2009;117:191-200.
11. Skyschally A, Gent S, Amanakis G, Schulte C, Kleinbongard P, Heusch G. Across-species transfer of protection by remote ischemic preconditioning with species-specific myocardial signal transduction by reperfusion injury salvage kinase and survival activating factor enhancement pathways. Circ Res 2015;117:279-288.
12. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD. Myocardial protection by brief ischemia in noncardiac tissue. Circulation 1996;94:2193-2200.
13. Mastitskaya S, Marina N, Gourine A, Gilbey MP, Spyer KM, Teschemacher AG, Kasparov S, Trapp S, Ackland GL, Gourine AV. Cardioprotection evoked by remote ischaemic preconditioning is critically dependent on the activity of vagal preganglionic neurones. Cardiovasc Res 2012;95:487-494.
14. Donato M, Buchholz B, Rodr_guez M, Pérez V, Inserte J, Garc_a-Dorado D, Gelpi RJ. Role of the parasympathetic nervous system in cardioprotection by remote hindlimb ischaemic preconditioning. Exp Physiol 2013;98:425-434.
15. Davidson SM, Selvaraj P, He D, Boi-Doku C, Yellon RL, Vicencio JM, Yellon DM. Remote ischaemic preconditioning involves signalling through the SDF-1a/CXCR4 signalling axis. Basic Res Cardiol 2013;108:377.
16. Rassaf T, Totzeck M, Hendgen-Cotta UB, Shiva S, Heusch G, Kelm M. Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning. Circ Res 2014;114:1601-1610.
17. Cai ZP, Parajuli N, Zheng X, Becker L. Remote ischemic preconditioning confers late protection against myocardial ischemia-reperfusion injury in mice by upregulating interleukin-10. Basic Res Cardiol 2012;107:277.
18. Li J, Rohailla S, Gelber N, Rutka J, Sabah N, Gladstone RA, Wei C, Hu P, Kharbanda RK, Redington AN. MicroRNA-144 is a circulating effector of remote ischemic preconditioning. Basic Res Cardiol 2014;109:423.
19. Hibert P, Prunier-Mirebeau D, Beseme O, Chwastyniak M, Tamareille S, Lamon D, Furber A, Pinet F, Prunier F. Apolipoprotein a-I is a potential mediator of remote ischemic preconditioning. PLoS One 2013;8:e77211.
20. Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG Jr. EGLN1 inhibition and rerouting of a-Ketoglutarate suffice for remote ischemic protection. Cell 2016;164:884-895.
21. Mastitskaya S, Basalay M, Hosford PS, Ramage AG, Gourine A, Gourine AV. Identifying the source of a humoral factor of remote (Pre)conditioning cardioprotection. PLoS One 2016;11:e0150108.
22. Calvillo L, Vanoli E, Andreoli E, Besana A, Omodeo E, Gnecchi M, Zerbi P, Vago G, Busca G, Schwartz PJ. Vagal stimulation, through its nicotinic action, limits infarct size and the inflammatory response to myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 2011;58:500-507.
23. Uitterdijk A, Yetgin T, te Lintel Hekkert M, Sneep S, Krabbendam-Peters I, van Beusekom HM, Fischer TM, Cornelussen RN, Manintveld OC, Merkus D, Duncker DJ. Vagal nerve stimulation started just prior to reperfusion limits infarct size and noreflow. Basic Res Cardiol 2015;110:508.
24. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014;114:1788-1803.
25. Drucker DJ. Deciphering metabolic messages from the gut drives therapeutic innovation: The 2014 Banting Lecture. Diabetes 2015;64:317-326.
26. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439.
27. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrientinduced glucagon-like peptide-1 secretion. Endocrinology 1999;140:1687-1694.
28. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 2008;117:2340-2350.
29. Ussher JR, Baggio LL, Campbell JE, Mulvihill EE, Kim M, Kabir MG, Cao X, Baranek BM, Stoffers DA, Seeley RJ, Drucker DJ. Inactivation of the cardiomyocyte glucagonlike peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1Rmediated cardioprotection. Mol Metab 2014;3:507-517.
30. Ravassa S, Zudaire A, Diez J. GLP-1 and cardioprotection: From bench to bedside. Cardiovasc Res 2012;94:316-323.
31. Lønborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, Jørgensen E, Helqvist S, Saunamaki K, Terkelsen CJ, Schoos MM, Køber L, Clemmensen P, Treiman M, Engstrøm T. Exenatide reduces final infarct size in patients with STsegment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012;5:288-295.
32. Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, Seon HJ, Kim KS. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 2013;33:2252-2260.
33. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med 2016;375:311-322.
34. Lang SC, Elsasser A, Scheler C, Vetter S, Tiefenbacher CP, Kübler W, Katus HA, Vogt AM. Myocardial preconditioning and remote renal preconditioning-identifying a protective factor using proteomic methods Basic Res Cardiol 2006;101:149-158.
35. Prechtl JC, Powley TL. Organization and distribution of the rat subdiaphragmatic vagus and associated paraganglia. J Comp Neurol 1985;235:182-195.
36. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268:19650-19655.
37. Thorens B, Porret A, Bühler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993;42:1678-1682.
38. Barrag_an JM, Eng J, Rodr_guez R, Bl_azquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 1999;277:E784-E791.
39. Bao W, Holt LJ, Prince RD, Jones GX, Aravindhan K, Szapacs M, Barbour AM, Jolivette LJ, Lepore JJ, Willette RN, DeAngelis E, Jucker BM. Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat. Cardiovasc Diabetol 2013;12:148.
40. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab 2016;24:15-30.
41. Pickard JM, Davidson SM, Hausenloy DJ, Yellon DM. Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning. Basic Res Cardiol 2016;111:50.
42. Gourine A, Gourine AV, Mastitskaya S, Ackland G. "Remote preconditioning reflex": A neural pathway of cardioprotection during myocardial ischaemia and reperfusion induced by remote ischemic preconditioning. Eur Heart J 2010;31:319.
43. Machhada A, Ang R, Ackland GL, Ninkina N, Buchman VL, Lythgoe MF, Trapp S, Tinker A, Marina N, Gourine AV. Control of ventricular excitability by neurons of the dorsal motor nucleus of the vagus nerve. Heart Rhythm 2015;12:2285-2293.
44. Machhada A, Marina N, Korsak A, Stuckey DJ, Lythgoe MF, Gourine AV. Origins of the vagal drive controlling left ventricular contractility. J Physiol 2016;594:4017-4030.
45. Hepponstall M, Ignjatovic V, Binos S, Monagle P, Jones B, Cheung MH, d'Udekem Y, Konstantinov IE. Remote ischemic preconditioning (RIPC) modifies plasma proteome in humans. PLoS One 2012;7:e48284.
46. Hibert P, Prunier-Mirebeau D, Beseme O, Chwastyniak M, Tamareille S, Pinet F, Prunier F. Modifications in rat plasma proteome after remote ischemic preconditioning (RIPC) stimulus: Identification by a SELDI-TOF-MS approach. PLoS One 2014;9:e85669.
47. Wallner M, Kolesnik E, Ablasser K, Khafaga M, Wakula P, Ljubojevic S, Thon-Gutschi EM, Sourij H, Kapl M, Edmunds NJ, Kuzmiski JB, Griffith DA, Knez I, Pieske B, von Lewinski D. Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. J Mol Cell Cardiol 2015;89:365-375.
48. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.J Clin Endocrinol Metab 1995;80:952-957.
49. Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 2002;146:863-869.
50. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemiareperfusion injury: Targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004;61:448-460.
51. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: Two sides of the same coin. Antioxid Redox Signal 2011;14:893-907.
52. Tamareille S, Mateus V, Ghaboura N, Jeanneteau J, Croué A, Henrion D, Furber A, Prunier F. RISK and SAFE signaling pathway interactions in remote limb ischemic perconditioning in combination with local ischemic postconditioning. Basic Res Cardiol 2011;106:1329-1339.
53. Xin P, Zhu W, Li J, Ma S, Wang L, Liu M, Li J, Wei M, Redington AN. Combined local ischemic postconditioning and remote perconditioning recapitulate cardioprotective effects of local ischemic preconditioning. Am J Physiol Heart Circ Physiol 2010;298:H1819-H1831.
54. Fuglesteg BN, Suleman N, Tiron C, Kanhema T, Lacerda L, Andreasen TV, Sack MN, Jonassen AK, Mjøs OD, Opie LH, Lecour S. Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion. Basic Res Cardiol 2008;103:444-453.
55. Lacerda L, Somers S, Opie LH, Lecour S. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 2009;84:201-208.
56. Suleman N, Somers S, Smith R, Opie LH, Lecour SC. Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc Res 2008;79:127-133.
57. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-151.
58. Heusch G, Musiolik J, Gedik N, Skyschally A. Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 2011;109:1302-1308.
59. Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M. STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: Short communication. Circ Res 2012;110:111-115.
60. Wang H, Lu Y, Wang Z. Function of cardiac M3 receptors. Auton Autacoid Pharmacol. 2007;27:1-11.
61. Heusch G, Gersh BJ. ERICCA and RIPHeart: Two nails in the coffin for cardioprotection by remote ischemic conditioning Probably not! Eur Heart J 2016;37:200-202.